Evogene Sharpening Focus on AI-Driven Molecule Design After Strategic Overhaul

Event summary

  • Evogene underwent a strategic transformation in 2025, focusing on its ChemPass AI™ platform.
  • The company narrowed its focus to two markets: human health (small-molecule therapeutics) and agriculture (agrochemicals).
  • Evogene divested non-core subsidiaries, including Lavie Bio (acquired by ICL) and licensed Biomica's lead candidate to Lishan Pharmaceuticals.
  • ChemPass AI™ is built on a 38-billion-molecule universe and has reportedly discovered development-candidate predictions now in testing with partners.
  • Evogene has established a business development team aligned with its refined strategy and is collaborating with Google Cloud.

The big picture

Evogene's strategic shift reflects a broader trend in the pharmaceutical and agricultural industries towards leveraging AI and computational chemistry to accelerate drug and agrochemical discovery. The company's focus on ChemPass AI™ and its partnerships with industry giants like Bayer and Corteva position it to capitalize on this trend, but also expose it to the risks associated with nascent technologies and geopolitical instability. The divestitures suggest a recognition that previous diversification efforts were not yielding sufficient returns.

What we're watching

Partnership Scale
The success of Evogene's strategy hinges on the ability to secure and expand partnerships in both human health and agriculture; the disclosed four collaborations need to translate into meaningful revenue and product pipeline growth.
ChemPass Validation
The efficacy of ChemPass AI™ beyond the initial collaborations will be critical; the platform's ability to consistently generate viable drug and agrochemical candidates needs to be demonstrated.
Geopolitical Risk
Ongoing geopolitical instability in the Middle East, as noted in the forward-looking statements, could significantly disrupt Evogene's operations and supply chains, impacting its ability to execute its strategic plan.

Related topics

Pharmaceuticals Capital Allocation Divestiture